Literature DB >> 21885244

Massive and submassive pulmonary embolism: experience with an algorithm for catheter-directed mechanical thrombectomy.

Naiem Nassiri1, Amit Jain, Diana McPhee, Bushra Mina, Robert J Rosen, Gary Giangola, Alfio Carroccio, Richard M Green.   

Abstract

BACKGROUND: The role of catheter-directed mechanical thrombectomy (CDMT) for the treatment of massive pulmonary embolism (MPE) and submassive pulmonary embolism (SMPE) is not clearly defined. We report our experience with an algorithm for CDMT as a primary treatment in patients with MPE and SMPE.
METHODS: We retrospectively reviewed our experience in treating MPE and SMPE in consecutive patients over a 2-year period (2008-2010). Patients with computed tomography angiography evidence of saddle, main branch, or ≥2 lobar pulmonary emboli in the setting of hypoxia, tachycardia, echocardiographic right heart strain, and/or cardiogenic shock underwent AngioJet CDMT, with or without adjunctive thrombolytic power-pulse spray. Outcomes, including angiographic success, clinical improvement, complications, and survival to discharge, were evaluated.
RESULTS: Fifteen patients (8 men, 7 women; 14 SMPE, 1 SMPE) with a mean age of 59 years (range: 35-90 years) were treated for heart strain (100%), tachycardia (67%), hypoxia (67%), and cardiogenic shock (7%). Ten patients (67%) also received Alteplase power-pulse spray. Resolution of symptoms and improvement in heart strain were achieved in all patients. There were no in-hospital mortalities. Complications occurred in 3 patients (20%), including 2 patients with acute tubular necrosis and 1 patient with an intraoperative cardiac arrest. Average hospitalization was 9 days (range: 4-26 days). All patients were discharged on full anticoagulation. None required supplemental oxygen at discharge.
CONCLUSION: CDMT as primary treatment of MPE and SMPE has a high rate of technical and clinical success in a high-risk patient population. Experience and strict patient selection criteria may improve therapeutic outcomes. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21885244     DOI: 10.1016/j.avsg.2011.05.026

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  5 in total

Review 1.  Endovascular treatment of pulmonary embolism: Selective review of available techniques.

Authors:  John L Nosher; Arjun Patel; Sugeet Jagpal; Christopher Gribbin; Vyacheslav Gendel
Journal:  World J Radiol       Date:  2017-12-28

2.  Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium.

Authors:  Belinda Rivera-Lebron; Michael McDaniel; Kamran Ahrar; Abdulah Alrifai; David M Dudzinski; Christina Fanola; Danielle Blais; David Janicke; Roman Melamed; Kerry Mohrien; Elizabeth Rozycki; Charles B Ross; Andrew J Klein; Parth Rali; Nicholas R Teman; Leoara Yarboro; Eugene Ichinose; Aditya M Sharma; Jason A Bartos; Mahir Elder; Brent Keeling; Harold Palevsky; Soophia Naydenov; Parijat Sen; Nancy Amoroso; Josanna M Rodriguez-Lopez; George A Davis; Rachel Rosovsky; Kenneth Rosenfield; Christopher Kabrhel; James Horowitz; Jay S Giri; Victor Tapson; Richard Channick
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

3.  Catheter-directed therapy for acute pulmonary embolism: navigating gaps in the evidence.

Authors:  Romain Chopard; Fiona Ecarnot; Nicolas Meneveau
Journal:  Eur Heart J Suppl       Date:  2019-11-21       Impact factor: 1.803

4.  Angiojet System Used in the Treatment of Submassive Pulmonary Embolism: A Case Report of Two Patients.

Authors:  Jinbo Liu; Tianrun Li; Wei Huang; Na Zhao; Hongwei Zhao; Hongyu Wang
Journal:  Case Rep Vasc Med       Date:  2022-08-23

5.  Treatment of high- and intermediate-risk pulmonary embolism using the AngioJet percutaneous mechanical thrombectomy system in patients with contraindications for thrombolytic treatment - a pilot study.

Authors:  Paweł Latacz; Marian Simka; Pawel Brzegowy; Wojciech Serednicki; Ewa Konduracka; Wojciech Mrowiecki; Agnieszka Słowik; Bartłomiej Łasocha; Tomasz Mrowiecki; Tadeusz Popiela
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-05-16       Impact factor: 1.195

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.